Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Gemcitabine and Radiation for Resectable Pancreatic Cancer
NCT00010166Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Dec 2000
- Primary completion
- Oct 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine in pancreatic cancer (PC), sponsored by Wake Forest University Health Sciences. Primary endpoints: Time to Disease Progression, Local Control and 1 more. Started Dec 2000; status: completed.
02
Drugs
gemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00010166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00010166.